Recent clinical data have demonstrated that presence of CD8 tumor infiltrating lymphocytes (TILs) and PD-L1 expression in tumor microenvironment have not only prognostic implication but also predict clinical response to PD-1 blockade immunotherapy in a number of malignant tumors [6, 7]. This evidence concerns the gene PDCD1 and cancer.